ClinicalTrials.gg
Active, not recruitingNCT05394116OPTIMAUpdated Nov 17, 2026Results posted

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 3 interventional study of Garetosmab and Placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 22 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).

The aim of the study is to see how safe and effective the study drug is in patients with FOP.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Keywords

  • Heterotopic Ossification (HO) Lesions
  • Type I activin A receptor (ACVR1)
  • Optima
  • LUMINA-1
  • Flare-Ups
03

In context

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

This study's enrollment of 63 is above the median of 48 across 16 interventional studies indexed under Myositis Ossificans.

Browse Myositis Ossificans studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive Heterotopic Ossification (HO)]
  2. Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
  3. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
  4. Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score at screening >19
  2. Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  3. Previous history or diagnosis of cancer
  4. Severely impaired renal function defined as estimated \<30 milliliter per minute (mL/min) (/1.73 m\^2 calculated by the Modification of Diet in Renal Disease equation
  5. Uncontrolled diabetes defined as (HbA1c) >9% at screening
  6. History of poorly controlled hypertension, as defined by:

    1. Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
    2. Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 10\^9 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, , peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
  7. Known history of cerebral vascular malformation
  8. Cardiovascular conditions such as class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia
  9. History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization
  10. Prior use in the past year and concomitant use of bisphosphonates
  11. Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples)
  12. Treatment with another drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer
  13. Pregnant or breastfeeding women
  14. Women of (WOCBP) who are unwilling to practice highly effective , as defined in the protocol
  15. Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure, as defined in the protocol

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    High dose Garetosmab

    Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)

    Drug: Garetosmab

  • Experimental
    Low dose Garetosmab

    Garetosmab is administered by IV administration Q4W

    Drug: Garetosmab

  • Experimental
    Placebo

    Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.

    Drug: Placebo

Interventions

  • Garetosmab is supplied as a liquid drug product and will be administered IV.

    Also known as: REGN2477, PASATRU™

  • DrugPlacebo

    Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.

06

What researchers measure

Primary outcomes

  1. Number of New Heterotopic Ossification (HO) Lesions

    The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline. This endpoint represents the cumulative number of New HO Lesions across all participants.

    Time frame: Week 56

  2. Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)

    The following were considered AESIs: * Epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling * Moderate-to-severe episodes of spontaneous non-traumatic bleeding * Moderate epistaxis * Severe epistaxis * Skin infection/abscess that requires referral to specialist for treatment

    Time frame: Baseline up to Week 56 [to include participants who discontinued earlier]

Secondary outcomes

  1. Number of Clinician-assessed Flare-ups

    Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants.

    Time frame: Baseline through Weeks 28 and 56

  2. Number of Participants With New HO Lesions at Weeks 28 and 56

    Reported as Yes/No The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

    Time frame: Weeks 28 and 56

  3. Total Volume of New HO Lesions

    The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

    Time frame: Weeks 28 and 56

  4. Percentage of Participants With Participant-reported Flare-ups

    Reported as Yes/No

    Time frame: Baseline through Weeks 28 and 56

  5. Number of New HO Lesions

    The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

    Time frame: Week 28

  6. Percentage of Participants With Clinician-assessed Flare-ups

    Reported as Yes/No

    Time frame: Baseline through Weeks 28 and 56

  7. Number of Participant-reported Flare-ups

    Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily. This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants.

    Time frame: Baseline through Weeks 28 and 56

  8. Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)

    CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30

    Time frame: Baseline, Weeks 28 and 56

  9. Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry

    Forced expiratory volume in 1 second (FEV1) will be determined by spirometry.

    Time frame: Baseline, Weeks 28 and 56

  10. Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)

    PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 (\[0\]: none, \[1\]: mild, \[2\]: moderate, \[3\]: severe, \[4\]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate

    Time frame: Baseline, Weeks 28 and 56

  11. Patient's Global Impression of Change (PGIC) Scale Score

    PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

    Time frame: Weeks 28 and 56

  12. Clinician's Global Impression of Change (CGIC) Scale Score

    CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

    Time frame: At Weeks 28 and 56

  13. Concentration of Total Activin A in Serum Over Time

    Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams \[mg\]/L) were set to 0.

    Time frame: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56

  14. Concentration of Garetosmab in Serum Over Time

    Concentrations below the LLOQ (0.078 mg/L) were set to 0.

    Time frame: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56

  15. Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time

    Time frame: Baseline through Week 56

  16. Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56

    Time frame: Baseline through Week 56

  17. Number of Clinician-assessed Flare-ups at Week 84

    Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment

    Time frame: Through Week 84

  18. Percentage of Participants With New HO Lesions at Week 84

    Reported as Yes/No Week 84 Only for Patients on Extended Treatment

    Time frame: At Week 84

  19. Total Volume of New HO Lesions

    Week 84 Only for Patients on Extended Treatment

    Time frame: At Week 84

  20. Number of New HO Lesions

    Week 84 Only for Participants on Extended Treatment

    Time frame: At week 84

  21. Percentage of Participants With Clinician-assessed Flare-ups

    Reported as Yes/No Week 84 Only for Participants on Extended Treatment

    Time frame: Through Week 84

  22. Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry

    FVC will be determined by spirometry.

    Time frame: Baseline, Weeks 28 and 56

  23. Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry

    The ratio of FEV1/FVC will be determined by spirometry.

    Time frame: Baseline, Weeks 28 and 56

07

Results

Posted Nov 17, 2026

Participant flow

Double-blind Treatment Period (DBTP)
Participant flow — Double-blind Treatment Period (DBTP)
MilestoneLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Started192321
Completed192320
Not completed001
Withdrew: Adverse event001
Extended Treatment Period (ETP)
Participant flow — Extended Treatment Period (ETP)
MilestoneLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Started192220
Completed192220
Not completed000

Outcome measures

PrimaryNumber of New Heterotopic Ossification (HO) Lesions

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline. This endpoint represents the cumulative number of New HO Lesions across all participants.

Time frame:
Week 56
Reported as:
Number · Lesions
Number of New Heterotopic Ossification (HO) Lesions
LesionsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Number of New Heterotopic Ossification (HO) Lesions1219
Statistical analysis
  • Low Dose Garetosmab vs Placebo · Negative Binomial Regression model · p = 0.0274 · Exponential of estimates from model: 0.06 · 95% CI 0.00 to 0.73
  • High Dose Garetosmab vs Placebo · Negative Binomial Regression model · p = 0.0260 · Exponential of estimates from model: 0.10 · 95% CI 0.01 to 0.76
PrimaryNumber of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)

The following were considered AESIs: * Epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling * Moderate-to-severe episodes of spontaneous non-traumatic bleeding * Moderate epistaxis * Severe epistaxis * Skin infection/abscess that requires referral to specialist for treatment

Time frame:
Baseline up to Week 56 [to include participants who discontinued earlier]
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)
ParticipantsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
TE-AESI041
Severe TE-AESI000
TE serious AESI010
Treatment-related TE-AESI041
TE-AESI leading to study treatment discontinuation000
TE-AESI leading to death000
SecondaryNumber of Clinician-assessed Flare-ups

Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants.

Time frame:
Baseline through Weeks 28 and 56
Reported as:
Number · Flare-ups
Number of Clinician-assessed Flare-ups
Flare-upsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 2838542
Week 5653966
SecondaryNumber of Participants With New HO Lesions at Weeks 28 and 56

Reported as Yes/No The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Time frame:
Weeks 28 and 56
Reported as:
Number · Participants
Number of Participants With New HO Lesions at Weeks 28 and 56
ParticipantsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 28113
Week 56125
SecondaryTotal Volume of New HO Lesions

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Time frame:
Weeks 28 and 56
Reported as:
Mean · cubic centimeters (cm^3)
Total Volume of New HO Lesions
cubic centimeters (cm^3)Low Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 280.01 ± 0.060.01 ± 0.046.02 ± 22.81
Week 560.01 ± 0.040.02 ± 0.0610.97 ± 37.37
SecondaryPercentage of Participants With Participant-reported Flare-ups

Reported as Yes/No

Time frame:
Baseline through Weeks 28 and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With Participant-reported Flare-ups
Percentage of participantsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 2857.943.547.6
Week 5657.947.861.9
SecondaryNumber of New HO Lesions

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Time frame:
Week 28
Reported as:
Number · Lesions
Number of New HO Lesions
LesionsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Number of New HO Lesions1111
SecondaryPercentage of Participants With Clinician-assessed Flare-ups

Reported as Yes/No

Time frame:
Baseline through Weeks 28 and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinician-assessed Flare-ups
Percentage of participantsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 2842.113.042.9
Week 5642.121.771.4
SecondaryNumber of Participant-reported Flare-ups

Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily. This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants.

Time frame:
Baseline through Weeks 28 and 56
Reported as:
Number · Flare-ups
Number of Participant-reported Flare-ups
Flare-upsLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 28686765
Week 5686109100
SecondaryChange From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)

CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30

Time frame:
Baseline, Weeks 28 and 56
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)
Score on a scaleLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Change at Week 28-0.4 ± 0.47-0.2 ± 0.42-0.3 ± 0.45
Change at Week 56-0.1 ± 0.510.0 ± 0.45-0.4 ± 0.48
SecondaryChange in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry

Forced expiratory volume in 1 second (FEV1) will be determined by spirometry.

Time frame:
Baseline, Weeks 28 and 56
Reported as:
Least squares mean · Liters (L)
Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry
Liters (L)Low Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 28-0.2702 ± 0.219070.0709 ± 0.23015-0.0019 ± 0.20468
Week 56-0.1237 ± 0.16475-0.5196 ± 0.17173-0.1384 ± 0.16561
SecondaryChange From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)

PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 (\[0\]: none, \[1\]: mild, \[2\]: moderate, \[3\]: severe, \[4\]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate

Time frame:
Baseline, Weeks 28 and 56
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)
Score on a scaleLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Change at Week 28-0.5 ± 0.17-0.7 ± 0.15-0.7 ± 0.16
Change at Week 56-0.4 ± 0.18-0.7 ± 0.16-0.5 ± 0.17
SecondaryPatient's Global Impression of Change (PGIC) Scale Score

PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

Time frame:
Weeks 28 and 56
Reported as:
Least squares mean · Score on a scale
Patient's Global Impression of Change (PGIC) Scale Score
Score on a scaleLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 282.7 ± 0.232.8 ± 0.213.2 ± 0.23
Week 562.7 ± 0.272.6 ± 0.243.1 ± 0.26
SecondaryClinician's Global Impression of Change (CGIC) Scale Score

CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

Time frame:
At Weeks 28 and 56
Reported as:
Least squares mean · Scores on a scale
Clinician's Global Impression of Change (CGIC) Scale Score
Scores on a scaleLow Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 282.8 ± 0.233.1 ± 0.223.3 ± 0.22
Week 562.7 ± 0.242.9 ± 0.223.1 ± 0.23
SecondaryConcentration of Total Activin A in Serum Over Time

Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams \[mg\]/L) were set to 0.

Time frame:
Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Reported as:
Mean · milligrams per Liter (mg/L)
Concentration of Total Activin A in Serum Over Time
milligrams per Liter (mg/L)PlaceboLow Dose GaretosmabHigh Dose Garetosmab
Day 1 (Week 0) predose0.000114 ± 0.0003130.000150 ± 0.0003580.000110 ± 0.000301
30 minutes after the end of infusion (nominal Week 0.003)0.000115 ± 0.0003490.000139 ± 0.0004490.000131 ± 0.000424
Week 10.000141 ± 0.0003210.0184 ± 0.006630.0240 ± 0.0106
Week 40.000120 ± 0.0002280.0237 ± 0.01450.0314 ± 0.0141
Week 80.000193 ± 0.0004480.0245 ± 0.008220.0382 ± 0.0175
Week 120.0000855 ± 0.0001800.0255 ± 0.007940.0377 ± 0.0159
Week 160.0000927 ± 0.0002030.0263 ± 0.009770.0371 ± 0.0130
Week 200.000153 ± 0.0004820.0298 ± 0.01330.0391 ± 0.0134
Week 280.000143 ± 0.0004310.0325 ± 0.01130.0370 ± 0.0133
Week 360.000157 ± 0.0005560.0279 ± 0.01030.0363 ± 0.0108
Week 400.0000166 ± 0.00007250.0297 ± 0.01150.0357 ± 0.0115
Week 440.0000174 ± 0.00007590.0280 ± 0.01010.0364 ± 0.0151
Week 480.0000428 ± 0.0001330.0261 ± 0.007810.0370 ± 0.0157
Week 520.0000442 ± 0.0001300.0274 ± 0.008460.0349 ± 0.0115
Week 560 ± 00.0284 ± 0.01090.0357 ± 0.0119
SecondaryConcentration of Garetosmab in Serum Over Time

Concentrations below the LLOQ (0.078 mg/L) were set to 0.

Time frame:
Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Reported as:
Mean · mg/L
Concentration of Garetosmab in Serum Over Time
mg/LLow Dose GaretosmabHigh Dose Garetosmab
Day 1 (Week 0) predose0 ± 00 ± 0
30 minutes after the end of infusion (nominal Week 0.003)55.2 ± 9.97174 ± 47.6
Week 127.3 ± 5.1196.1 ± 23.4
Week 412.4 ± 2.9743.7 ± 13.4
Week 818.1 ± 6.3371.0 ± 28.7
Week 1222.3 ± 7.2879.9 ± 31.4
Week 1623.3 ± 8.4478.9 ± 30.7
Week 2025.1 ± 9.7693.7 ± 36.0
Week 2824.6 ± 7.5488.3 ± 38.3
Week 3623.5 ± 7.4993.1 ± 39.5
Week 4024.5 ± 8.02128 ± 141
Week 4422.9 ± 8.1294.4 ± 37.1
Week 4823.1 ± 7.7896.7 ± 40.5
Week 5222.2 ± 6.62105 ± 57.0
Week 5623.5 ± 6.7590.4 ± 38.4
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
Time frame:
Baseline through Week 56
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
ParticipantsPlaceboLow Dose GaretosmabHigh Dose Garetosmab
Treatment-Boosted Response000
Treatment-Emergent Response000
SecondaryNumber of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
Time frame:
Baseline through Week 56
Reported as:
Count of participants · Participants
Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
ParticipantsPlaceboLow Dose GaretosmabHigh Dose Garetosmab
Low (<1,000)000
Moderate (1,000 to 10,000)000
High (>10,000)000
SecondaryNumber of Clinician-assessed Flare-ups at Week 84

Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment

Time frame:
Through Week 84

Results for this outcome have not been posted.

SecondaryPercentage of Participants With New HO Lesions at Week 84

Reported as Yes/No Week 84 Only for Patients on Extended Treatment

Time frame:
At Week 84

Results for this outcome have not been posted.

SecondaryTotal Volume of New HO Lesions

Week 84 Only for Patients on Extended Treatment

Time frame:
At Week 84

Results for this outcome have not been posted.

SecondaryNumber of New HO Lesions

Week 84 Only for Participants on Extended Treatment

Time frame:
At week 84

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Clinician-assessed Flare-ups

Reported as Yes/No Week 84 Only for Participants on Extended Treatment

Time frame:
Through Week 84

Results for this outcome have not been posted.

SecondaryChange in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry

FVC will be determined by spirometry.

Time frame:
Baseline, Weeks 28 and 56
Reported as:
Least squares mean · Liters (L)
Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry
Liters (L)Low Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 280.7586 ± 0.38391-0.1712 ± 0.455960.2713 ± 0.37088
Week 560.0811 ± 0.15013-0.1001 ± 0.131660.1368 ± 0.11480
SecondaryChange in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry

The ratio of FEV1/FVC will be determined by spirometry.

Time frame:
Baseline, Weeks 28 and 56
Reported as:
Least squares mean · Liters per Liters (L/L)
Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry
Liters per Liters (L/L)Low Dose GaretosmabHigh Dose GaretosmabPlacebo
Week 280.001 ± 0.0161-0.031 ± 0.0170-0.028 ± 0.0141
Week 560.025 ± 0.0259-0.072 ± 0.0241-0.026 ± 0.0206

Adverse events

Collected over From the date of signing the Informed Consent Form (ICF) up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Garetosmab 3 mg0/19 (0%)1/19 (5.3%)18/19 (94.7%)
High Dose Garetosmab 10 mg0/23 (0%)2/23 (8.7%)22/23 (95.7%)
Placebo0/21 (0%)2/21 (9.5%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventLow Dose Garetosmab 3 mgHigh Dose Garetosmab 10 mgPlacebo
Dengue feverInfections and infestations1/190/230/21
PneumoniaInfections and infestations1/190/230/21
Peritonsillar abscessInfections and infestations0/190/231/21
Ovarian cystReproductive system and breast disorders0/190/231/21
AbscessInfections and infestations0/191/230/21
CellulitisInfections and infestations0/191/230/21
Most frequent other events
Showing 10 of 124
Most frequent other events
EventLow Dose Garetosmab 3 mgHigh Dose Garetosmab 10 mgPlacebo
EpistaxisRespiratory, thoracic and mediastinal disorders10/194/235/21
ArthralgiaMusculoskeletal and connective tissue disorders5/194/239/21
Pain in extremityMusculoskeletal and connective tissue disorders2/190/238/21
AcneSkin and subcutaneous tissue disorders3/197/232/21
Back painMusculoskeletal and connective tissue disorders1/191/236/21
Fibrodysplasia ossificans progressivaCongenital, familial and genetic disorders5/193/236/21
RashSkin and subcutaneous tissue disorders5/191/230/21
NasopharyngitisInfections and infestations5/191/235/21
MadarosisSkin and subcutaneous tissue disorders3/196/234/21
Musculoskeletal painMusculoskeletal and connective tissue disorders1/190/235/21

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Low Dose GaretosmabHigh Dose GaretosmabPlaceboTotal
Mean24.6 ± 6.025.7 ± 6.329.3 ± 7.326.6 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose GaretosmabHigh Dose GaretosmabPlaceboTotal
Female12151138
Male781025
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Dose GaretosmabHigh Dose GaretosmabPlaceboTotal
Hispanic or Latino25512
Not Hispanic or Latino15181548
Unknown or Not Reported2013
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Dose GaretosmabHigh Dose GaretosmabPlaceboTotal
White11181342
Black or African American0101
Asian84719
American Indian / Alaskan Native0000
Native Hawaiian or Other Pacific Islander0000
Not Reported0000
Other0000
Unknown0011
08

Study locations

22 sites
09

References and documents

Publications

  • Papa R, Rhee S, Delai P, Zhang K, Balcazar IB, Rethanavelu K, Fujiwara T, Mishima K, Tabarkiewicz J, Funck-Brentano T, Stander R, Bachiller-Corral J, Dahir KM, Eekhoff EMW, Hero M, Kuong E, Uemura N, Zhou M, Trotter DG, Gu J, Sanchez RJ, O'Donovan DO, Economides AN, Pordy R, Hirshberg B, Yancopoulos GD, Keen R; OPTIMA Study Group. Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2026 Sep 28:S0140-6736(26)01599-0. doi: 10.1016/S0140-6736(26)01599-0. Online ahead of print. PubMed 42805227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jul 2025, 31 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion. A results delay was requested in Jul 2026.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 27, 2022
StartActual
Nov 21, 2022
Primary completionActual
Jul 17, 2025
CompletionEst.
Feb 27, 2029
Results delay requested
Jul 15, 2026
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of new New Heterotopic Ossification (HO lesions) LesionsTime frame: At Week 56 → Week 56
  • EditedIncidence and severityNumber of treatmentParticipants With Treatment-emergent adverse events(TE) Adverse Events of special interestSpecial Interest (AESIs)Time frame: Baseline to Week 56 → Baseline up to Week 56 [to include participants who discontinued earlier]
Nov 17, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42805227 ↗
Nov 17, 2026
Secondary outcomes
16 edited, 7 added
What changed in the outcomes
  • EditedNumber of clinicianClinician-assessed flareFlare-upsTime frame: Through Weeks 28, 56 and 84 → Baseline through Weeks 28 and 56
  • EditedOccurrenceTotal Volume of newNew HO lesionsLesionsTime frame: At Weeks 28, 56 and 84 → Weeks 28 and 56
  • EditedTotal volumeNumber of newNew HO lesionsLesionsTime frame: At Weeks 28, 56 and 84 → Week 28
  • EditedOccurrencePercentage of patientParticipants With Participant-reported flareFlare-upsTime frame: Through Weeks 28 and 56 → Baseline through Weeks 28 and 56
  • EditedNumber of newParticipants With New HO lesionsLesions at Weeks 28 and 56Time frame: At week 28 and 84 → Weeks 28 and 56
  • EditedOccurrencePercentage of clinicianParticipants With Clinician-assessed flareFlare-upsTime frame: Through Weeks 28, 56 and 84 → Baseline through Weeks 28 and 56
  • EditedNumber of patientParticipant-reported flareFlare-upsTime frame: Through Weeks 28 and 56 → Baseline through Weeks 28 and 56
  • EditedChange From Baseline in joint function assessmentJoint Function Assessment by physician using cumulative analog joint involvement scalePhysician Using Cumulative Analog Joint Involvement Scale (CAJIS)Time frame: Baseline to Weeks 28 and 56 → Baseline, Weeks 28 and 56
  • EditedChange in pulmonary functionPulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as assessedAssessed by spirometrySpirometryTime frame: Baseline at Weeks 28 and 56 → Baseline, Weeks 28 and 56
  • EditedChange From Baseline in disease severityDisease Severity as assessedAssessed by the Patient Global Impression of Severity (PGIS)Time frame: Baseline to Weeks 28 and 56 → Baseline, Weeks 28 and 56
  • EditedChange in disease severity as assessed by the Patient's Global Impression of Change (PGIC) Scale ScoreTime frame: At Weeks 28 and 56 → Weeks 28 and 56
  • EditedChange in disease severity as assessed by the Clinician's Global Impression of Change (CGIC) Scale ScoreTime frame: At Weeks 28 and 56
  • EditedConcentration of total activinTotal Activin A in serum over timeSerum Over TimeTime frame: Through Week 56 → Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
  • EditedConcentration of garetosmabGaretosmab in serum over timeSerum Over TimeTime frame: Through Week 56 → Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
  • EditedIncidenceNumber of antiParticipants With Anti-drug antibodiesAntibodies (ADA) to garetosmab over timeGaretosmab Over TimeTime frame: Through Week 56 → Baseline through Week 56
  • EditedNumber of Participants With Titer Values of ADA to garetosmab over timeGaretosmab Over Time Through Week 56Time frame: Through Week 56 → Baseline through Week 56
  • AddedNumber of Clinician-assessed Flare-ups at Week 84Time frame: Through Week 84
  • AddedPercentage of Participants With New HO Lesions at Week 84Time frame: At Week 84
  • AddedTotal Volume of New HO LesionsTime frame: At Week 84
  • AddedNumber of New HO LesionsTime frame: At week 84
  • AddedPercentage of Participants With Clinician-assessed Flare-upsTime frame: Through Week 84
  • AddedChange in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by SpirometryTime frame: Baseline, Weeks 28 and 56
  • AddedChange in Pulmonary Function (FEV1/FVC) as Assessed by SpirometryTime frame: Baseline, Weeks 28 and 56
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42805227 ↗
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of new New Heterotopic Ossification (HO lesions) LesionsTime frame: At Week 56 → Week 56
    • EditedIncidence and severityNumber of treatmentParticipants With Treatment-emergent adverse events(TE) Adverse Events of special interestSpecial Interest (AESIs)Time frame: Baseline to Week 56 → Baseline up to Week 56 [to include participants who discontinued earlier]
    Secondary outcomes 16 edited, 7 added
    What changed in the outcomes
    • EditedNumber of clinicianClinician-assessed flareFlare-upsTime frame: Through Weeks 28, 56 and 84 → Baseline through Weeks 28 and 56
    • EditedOccurrenceTotal Volume of newNew HO lesionsLesionsTime frame: At Weeks 28, 56 and 84 → Weeks 28 and 56
    • EditedTotal volumeNumber of newNew HO lesionsLesionsTime frame: At Weeks 28, 56 and 84 → Week 28
    • EditedOccurrencePercentage of patientParticipants With Participant-reported flareFlare-upsTime frame: Through Weeks 28 and 56 → Baseline through Weeks 28 and 56
    • EditedNumber of newParticipants With New HO lesionsLesions at Weeks 28 and 56Time frame: At week 28 and 84 → Weeks 28 and 56
    • EditedOccurrencePercentage of clinicianParticipants With Clinician-assessed flareFlare-upsTime frame: Through Weeks 28, 56 and 84 → Baseline through Weeks 28 and 56
    • EditedNumber of patientParticipant-reported flareFlare-upsTime frame: Through Weeks 28 and 56 → Baseline through Weeks 28 and 56
    • EditedChange From Baseline in joint function assessmentJoint Function Assessment by physician using cumulative analog joint involvement scalePhysician Using Cumulative Analog Joint Involvement Scale (CAJIS)Time frame: Baseline to Weeks 28 and 56 → Baseline, Weeks 28 and 56
    • EditedChange in pulmonary functionPulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as assessedAssessed by spirometrySpirometryTime frame: Baseline at Weeks 28 and 56 → Baseline, Weeks 28 and 56
    • EditedChange From Baseline in disease severityDisease Severity as assessedAssessed by the Patient Global Impression of Severity (PGIS)Time frame: Baseline to Weeks 28 and 56 → Baseline, Weeks 28 and 56
    • EditedChange in disease severity as assessed by the Patient's Global Impression of Change (PGIC) Scale ScoreTime frame: At Weeks 28 and 56 → Weeks 28 and 56
    • EditedChange in disease severity as assessed by the Clinician's Global Impression of Change (CGIC) Scale ScoreTime frame: At Weeks 28 and 56
    • EditedConcentration of total activinTotal Activin A in serum over timeSerum Over TimeTime frame: Through Week 56 → Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
    • EditedConcentration of garetosmabGaretosmab in serum over timeSerum Over TimeTime frame: Through Week 56 → Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
    • EditedIncidenceNumber of antiParticipants With Anti-drug antibodiesAntibodies (ADA) to garetosmab over timeGaretosmab Over TimeTime frame: Through Week 56 → Baseline through Week 56
    • EditedNumber of Participants With Titer Values of ADA to garetosmab over timeGaretosmab Over Time Through Week 56Time frame: Through Week 56 → Baseline through Week 56
    • AddedNumber of Clinician-assessed Flare-ups at Week 84Time frame: Through Week 84
    • AddedPercentage of Participants With New HO Lesions at Week 84Time frame: At Week 84
    • AddedTotal Volume of New HO LesionsTime frame: At Week 84
    • AddedNumber of New HO LesionsTime frame: At week 84
    • AddedPercentage of Participants With Clinician-assessed Flare-upsTime frame: Through Week 84
    • AddedChange in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by SpirometryTime frame: Baseline, Weeks 28 and 56
    • AddedChange in Pulmonary Function (FEV1/FVC) as Assessed by SpirometryTime frame: Baseline, Weeks 28 and 56
    + 5 other changes: identifiers, verification date, registry dates, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05394116
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Nov 21, 2022
Primary completion
Jul 17, 2025
Completion
Feb 27, 2029 (estimated)
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion